vTv Therapeutics(VTVT) - 2024 Q4 - Annual Results

Financial Position - vTv Therapeutics reported a cash position of $36.7 million as of December 31, 2024, compared to$9.4 million as of December 31, 2023, reflecting a significant increase due to private placement financing[6] - Interest income for the year ended December 31, 2024, was $1.6 million, up from$0.5 million in 2023, reflecting improved financial management[6] Research and Development - Research and Development (R&D) expenses for Q4 2024 were $2.2 million, slightly up from$2.1 million in Q4 2023, while full-year R&D expenses decreased to $11.5 million from$13.6 million in 2023[6] - The FDA lifted the clinical hold on the cadisegliatin program on March 14, 2025, allowing the CATT1 Phase 3 trial to resume in Q2 2025[3] - The CATT1 Phase 3 trial protocol will be amended to reduce the trial duration from 12 months to 6 months, expediting the timeline for topline data[2] Operating Expenses - General and Administrative (G&A) expenses for Q4 2024 were $2.7 million, compared to$2.6 million in Q4 2023, with full-year G&A expenses increasing to $13.7 million from$11.9 million in 2023[6] - Total operating expenses for Q4 2024 were $4.9 million, compared to$4.7 million in Q4 2023, while full-year operating expenses were $25.2 million, slightly down from$25.5 million in 2023[10] Net Loss - The net loss attributable to vTv shareholders for Q4 2024 was $3.6 million, or$0.55 per basic share, compared to a net loss of $3.5 million, or$1.67 per basic share, in Q4 2023[6] - For the full year 2024, the net loss attributable to vTv shareholders was $18.5 million, or$3.20 per basic share, down from a net loss of $20.3 million, or$9.71 per basic share, in 2023[6] Leadership Changes - Martin Lafontaine was appointed as Chief Commercial Officer to enhance commercial leadership and support the cadisegliatin program[3]